143 related articles for article (PubMed ID: 37793761)
1. Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma.
Rodriguez-Otero P; Tamariz LE; San-Miguel JF
Lancet Haematol; 2023 Oct; 10(10):e786-e787. PubMed ID: 37793761
[No Abstract] [Full Text] [Related]
2. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
3. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
4. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
Sheikh S; Lebel E; Trudel S
Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
[TBL] [Abstract][Full Text] [Related]
5. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
6. Belantamab mafodotin for the treatment of multiple myeloma.
Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
[TBL] [Abstract][Full Text] [Related]
7. Belantamab mafodotin for relapsed or refractory multiple myeloma.
Gil-Sierra MD; Briceño-Casado MDP
J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
[No Abstract] [Full Text] [Related]
8. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
[TBL] [Abstract][Full Text] [Related]
12. Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma.
Zhang Y; Godara A; Pan S; Toskic D; Mann H; Sborov D; Comenzo R; Kansagra A
Ann Hematol; 2022 Sep; 101(9):2119-2121. PubMed ID: 35821344
[No Abstract] [Full Text] [Related]
13. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
[TBL] [Abstract][Full Text] [Related]
14. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
15. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
[TBL] [Abstract][Full Text] [Related]
16. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
Rodríguez Otero P; Towle K; Cope S; Caisip C; Davies FE; Delforge M; Weisel K; Marshall TS; Karampampa K; Ayers D; Mojebi A; Braverman J; Farrell J; Dhanda D
Leuk Lymphoma; 2023; 64(11):1864-1869. PubMed ID: 37497883
[No Abstract] [Full Text] [Related]
17. Belantamab mafodotin in multiple myeloma.
Martino EA; Bruzzese A; Iaccino E; Labanca C; Mendicino F; Mimmi S; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Biol Ther; 2023; 23(11):1043-1047. PubMed ID: 37227998
[No Abstract] [Full Text] [Related]
18. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
[TBL] [Abstract][Full Text] [Related]
20. "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.
Vaxman I; Abeykoon J; Dispenzieri A; Kumar SK; Buadi F; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Reeder C; Sher T; Hayman S; Kourelis T; Warsame R; Muchtar E; Leung N; Go R; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Kristen M; Kapoor P; Gertz MA
Blood Cancer J; 2021 Dec; 11(12):196. PubMed ID: 34876555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
